# Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

> **NCT05807542** · PHASE2 · COMPLETED · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 20 (actual)

## Conditions studied

- Esophagus Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Paclitaxel-albumin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05807542
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05807542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05807542, "Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05807542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*